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Abstract
Although the acute manifestations of Chikungunya virus (CHIKV) illness are well-documented, few data exist about the
long-term rheumatic outcomes of CHIKV-infected patients. We undertook between June and September 2006 a
retrospective cohort study aimed at assessing the course of late rheumatic manifestations and investigating potential risk
factors associated with the persistence of these rheumatic manifestations over 15 months. 147 participants (.16 yrs) with
laboratory-confirmed CHIKV disease diagnosed between March 1 and June 30, 2005, were identified through a surveillance
database and interviewed by telephone. At the 15-month-period evaluation after diagnosis, 84 of 147 participants (57%)
self-reported rheumatic symptoms. Of these 84 patients, 53 (63%) reported permanent trouble while 31 (37%) had recurrent
symptoms. Age $45 years (OR=3.9, 95% CI 1.7–9.7), severe initial joint pain (OR=4.8, 95% CI 1.9–12.1), and presence of
underlying osteoarthritis comorbidity (OR=2.9, 95% CI 1.1–7.4) were predictors of nonrecovery. Our findings suggest that
long-term CHIKV rheumatic manifestations seem to be a frequent underlying post-epidemic condition. Three independent
risk factors that may aid in early recognition of patients with the highest risk of presenting prolonged CHIKV illness were
identified. Such findings may be particularly useful in the development of future prevention and care strategies for this
emerging virus infection.
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Introduction
Chikungunya virus (CHIKV, family Togaviridae, genus Alphavirus)
is a mosquito-borne virus belonging to the Semliki Forest
serocomplex, which includes Ross River virus (RRV), O’nyong-nyong
(ONN), Mayaro (MAY), and Barmah Forest viruses (BFV). Common
clinical manifestations caused by these viruses include abrupt onset
of fever, headache, backache, and arthralgia [1].
Since its initial identification in Newala province (Tanzania) in
1953 [2], CHIKV has been associated with numerous outbreaks,
mainly in Africa [3,4] and Asia [5,6]. In early 2005, CHIKV was
introduced into the Southwestern Indian Ocean region, probably
from infected viraemic travellers arriving from Lamu (Kenya),
where an outbreak started in June 2004 [7]. Subsequently, it
rapidly spread across the Southwestern Indian Ocean islands
(Comoros, Madagascar, Mayotte, Seychelles, Mauritius, Reunion
Island), resulting in an extensive regional epidemic in 2005 and
2006 [8–12]. Afterward, these outbreaks’ viruses expanded into
Asian countries [13,14]. Concurrently, numerous imported cases
were noticed in nontropical Western countries [15,16]. Moreover,
these imported cases raised concerns about the possibility of the
emergence of CHIKV infection in Europe, as Aedes albopictus, the
mosquito vector of CHIKV in Reunion Island [17], is present in
several European countries [18], including Italy, where it was first
recorded in the 1990s and is particularly common [19]. Indeed,
this concern was born out by documentation of an autochthonous
CHIKV outbreak in the Ravenna region of Italy during the
summer of 2007, which was linked to a viraemic index patient
originating in Kerala, India [20].
In Reunion Island, CHIKV outbreak evolved in two-wave
phenomena with a first wave between March to June 2005 and the
second one from December 2005 to June 2006. The overall attack
rate in Reunion Island was estimated to be 35% in mid-2006.
Subsequently, CHIKV presented with an endemo-sporadic
pattern until the beginning of 2007, when it disappeared.
However, in spite of this, chronic rheumatic symptoms have
persisted in many previously infected individuals.
Rheumatic manifestations of CHIKV infection typically consist
of a febrile arthritis principally affecting the extremities (ankles,
wrists, phalanges), although many others joints may be affected
[21]. Patients adopt a characteristic stooped walking position
which is the hallmark of the disease and from which it derives its
name Chikungunya, meaning ‘‘he who walks bent over’’, in the
Kimakonde language of Mozambique. Although the acute
www.plosntds.org 1 March 2009 | Volume 3 | Issue 3 | e389rheumatic involvement is well-documented, less is known about
the potential long-term clinical and functional outcome [21–23].
To our knowledge, the most detailed description is a cohort of 107
patients by Brighton et al. [24], which indicated that nearly 12%
of patients had not fully recovered three years after initial
infection. In that study, determinants of the course of rheumatic
manifestations of CHIKV infections were not investigated.
In order to address these shortcomings, we have evaluated
rheumatic complications in a cohort of Reunion Island residents
infected with CHIKV during the initial phase of the epidemic in
2005. The study had two objectives, firstly to assess the course of
rheumatic manifestations over the 15 months following the acute
illness, and secondly to investigate potential risk factors associated
with long-term outcome.
Materials and Methods
Design
This study was conducted on Reunion Island, a French territory
in the Southwest Indian Ocean. We used a community-based,
retrospective cohort design involving 3,539 presumptive or
laboratory-confirmed cases of CHIKV illness that were reported
to the local health authority during the first wave of this outbreak
(March–June 2005). Recruited persons were interviewed by
telephone between June 1 and September 15, 2006.
Participants
In order to identify potentially eligible participants, we used a
case notification surveillance database which has previously been
described elsewhere. Patients aged more than 16 years old with
serologically confirmed CHIKV infection were invited to partici-
pate. Seropositivity was defined as the presence of CHIKV-specific
immunoglobulin [Ig] M antibody by IgM-capture enzyme-linked
immunosorbent assay or detection of CHIKV in body fluids by
amplification of CHIKV RNA using reverse transcriptase–poly-
merase chain reaction (RT–PCR). Other inclusion criteria included
disease onset between March 1 and June 30, 2005, a telephone
number accessible through the database, and provision of oral
informed consent for all participants or from parents or guardians
for those less than 18 years of age.
Data Collection
Data were collected by a trained physician using a standardised
structured questionnaire in French, which was developed for the
purposes of the study and administered by telephone interview.
Collected information included: demographic characteristics
(age, gender, educational level, employment status, marital status),
major comorbidities, acute rheumatic manifestations (anatomical
location, date of onset, duration of symptoms, and pain intensity),
hospitalisation, treatment received (medications, physiotherapy,
alternative and complementary therapies), subjective treatment
satisfaction, and impact of illness on professional or household or
daily activities. Moreover, chronic rheumatic manifestations (in
particular, the duration of morning stiffness of $45 minutes as a
typical sign of inflammatory pattern) at month 15 following
infection were assessed. For both acute and chronic manifestations,
pain intensity was evaluated using a declarative numerical rating
scale (NRS) [25]. This scale could be scored between 0 and 10, with
higher values indicating more severe pain. Scores were categorised
into three classes (mild: 1–4; moderate: 5–6; or severe: 7–10).
Outcomes
The primary outcome measure was self-perceived recovery
from rheumatic manifestations of CHIKV infections at 15 months
following disease onset. This was assessed by asking two questions
with bimodal (yes/no) response modes. The first question was ‘‘Do
you feel that you have made a complete recovery from joint
manifestations since being diagnosed as having a CHIKV
infection?’’ For those who replied affirmatively, a subsidiary
question was asked: ‘‘Over the past eight days, did symptoms of
CHIKV illness subside and subsequently recur?’’. This allowed
permanently asymptomatic (remitted) patients to be differentiated
from those who had experienced a relapse within the past eight
days. Patients replying negatively to the first question and
affirmatively to the second were combined in a ‘‘persistence’’
group. The analysis compared this ‘‘persistence’’ group to a
‘‘remission’’ group who replied negatively to the second question.
Statistical Analysis
To identify potential risk factors for persistence of rheumatic
manifestations, the twooutcome groups were compared by univariate
and multivariate unconditional logistic regression. All variables were
firstly assessed individually in a univariate model, and odds ratios
(OR) estimated with their corresponding 95% confidence intervals
(CIs) and P-values determined with the x
2 likelihood test. Parameters
whose distribution varied between groups at a probability level of
P,0.25 were retained and entered into a multivariate logistic
regression analysis using a forward stepwise selection procedure.
Multivariate analysis was conducted with adjustment for gender.
Possible interactions and multi-colinearity were examined. If two or
more potential factors risk were highly correlated, the predictor that
was considered to be more clinically important was selected for entry.
Finally, the goodness-of-fit of the final model was assessed using the
logistic regression diagnostics procedure. A probability value of #.05
(two-tailed) was taken to be statistically significant. Statistical analyses
were performed with STATA software, version 9 (STATA Corp.,
College Station, Texas, United States).
Ethical Considerations
The survey design was approved by both the French Data
Protection Authority (Commission Nationale Informatique et Liberte ´) and
the National Council for Statistical Information (CNIS).
Author Summary
Transmitted by day-biting mosquitoes, Chikungunya virus
(CHIKV), causing febrile illness and joint pain, is widespread
in Africa and Asia. Recent outbreaks in the Indian Ocean
islands, its rapid expansion across continents, and its
unusual clinical acute pattern have shed light on and
brought awareness of this re-emerging virus. However,
late rheumatic manifestations of this infection remain
poorly examined. Thus, we have evaluated over a 15-
month period the evolution and assessed potential risk
factors of CHIKV-related rheumatic manifestations in a
cohort of Reunion Island residents infected with CHIKV
during the initial phase of the epidemic in 2005. Eligible
adult patients were identified through a surveillance
database. We found that rheumatic symptoms lasted for
at least 15 months in 57% of the participants. Of these,
63% reported permanent trouble while 37% had recurrent
symptoms. Factors such as age $45 years, severe initial
joint pain, and presence of underlying osteoarthritis
comorbidity were associated with nonrecovery over the
15-month period. Our findings suggest that long-term
CHIKV rheumatic manifestations seem to be a hidden,
frequent, post-epidemic condition. These findings should
be considered in the development of preventive measures.
Risk Factors of Long-Term Chikungunya Rheumatism
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Participants
In total, 3,539 presumptive or laboratory-confirmed CHIKV
infection cases were reported between March 1 and June 30, 2005.
CHIKV infection was confirmed serologically for 873 cases. Of
these, 713 persons were excluded for the following reasons: no
phone contact (n=465); unknown date of CHIKV infection
(n=248). Of the remaining 160 patients who were invited to
participate, 147 provided oral informed consent (92%) and
constituted the study population.
This study population included 69% women and 31% men.
The mean age of the patients was 52 years (SD: 15). Nearly 31% of
the patients were age less than 45 years old, and 21% were more
than 65 years old. Only 67 patients (45%) were working or
studying at the time of the onset of their CHIKV illness. The
median time elapsed between the onset of CHIKV illness and the
interview was 439 days (range, 370 to 508 days). The most
frequently encountered medical comorbidities were hypertension
in 48 patients (33%), osteoarthritis in 38 (26%), and diabetes
mellitus in 32 (22%) (Table 1).
Disease Characteristics and Health Care Utilisation
Table 2 presents the frequency and course of rheumatic
symptoms. All 147 patients reported joint pain during the initial
phase of the disease. Joint pain was reported as symmetrical in
96% of patients. The principal locations of rheumatic symptoms
were the ankles in 112 (76%), the wrists in 91 (62%), the knees in
65 (44%), the fingers in 79 (54%), and the toes in 84 (57%) of the
patients. More than four joints were affected (polyarthritis) in 76%
of the patients.
Overall, 137 (93%) declared having been prescribed paracet-
amol. Among these, 106 (77%) reported a combination of
paracetamol with a nonsteroid anti-inflammatory drug (NSAID).
Nearly half of the patients (46%) were taking medicinal plants as
complementary therapy. Corticosteroids were prescribed to 23%
Table 1. Baseline characteristics of participants with
confirmed CHIKV infection (N=147), Reunion Island, 2005–
2006.
Variable Subcategory Result (%)
Age in years, median
(range)
52 (16–86)
,25 11 (7.5)
25–44 34 (23.1)
45–64 72 (49.0)
$65 30 (20.4)
Gender Male 45 (31)
Female 102 (69)
Schooling in years 0–6 50 (34)
7–9 62 (42)
$10 35 (24)
Employment status Studying 5 (3)
Salaried employment 62 (42)
Unemployed 17 (12)
Retired 42 (29)
Housewife 21 (14)
Marital status Married 81 (55.5)
Living alone (single, separated,
widowed)
66 (44.5)
Presence of
comorbidities
76 (52)
Type of comorbidity* Diabetes mellitus 32 (22)
Hypertension 48 (33)
Osteoarthritis 38 (26)
Chronic cardiac disease 14 (10)
*Only comorbidities present in $10 percent of patients are listed.
doi:10.1371/journal.pntd.0000389.t001
Table 2. Acute clinical characteristics and treatment among
participants with confirmed CHIKV infection (N=147),
Reunion Island, 2005–2006.
Variable Subcategory Result (%)
Time since onset in days Mean6standard deviation 438638
Median 439
Range 370–508
Initial rheumatic symptoms Joint pain 147 (100)
Joint stiffness 134 (91)
Join swelling 103 (70)
Initial joint pain intensity
(NRS* score)
Mild 5 (3.4)
Moderate 28 (19)
Severe 114 (77.6)
Main joints affected initially Ankles 112 (76)
Wrists 91 (62)
Toe joints 84 (57)
Finger joints 79 (54)
Knees 65 (44)
Initial arthritis presentation Oligoarthritis (2–4 joints) 35 (24)
Polyarthritis (.4 joints) 112 (76)
Symptom duration in days ,15 34 (23)
15–30 20 (14)
.30 93 (63)
Lifestyle impact Missed school or work** 40 (66.6)
Household or daily activities 113 (75)
Medical care Hospitalisation 22 (15)
NSAID*** 114 (78)
Paracetamol 137 (93)
Corticosteroids 34 (23)
Medicinal plants 68 (46)
Physical or occupational
therapy
29 (20)
Perceived satisfaction with
treatment
NSAID 41/114 (36)
Paracetamol 47/137 (34)
Corticosteroids 26/34 (76)
Medicinal plants 21/68 (31)
Physical or occupational
therapy
4/29 (14)
*Numerical rating scale.
**among employed.
***nonsteroid anti-inflammatory drug.
doi:10.1371/journal.pntd.0000389.t002
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of patients reported being satisfied with their medication, with the
exception of those taking corticosteroids, who were more satisfied
(76%).
During the acute phase, 22 (15%) patients were hospitalised
with a median length of stay of five days (range: 1 to 22 days).
Disease Course, Impact, and Risk Factors for Persistence
Overall, 63 (43%) declared being completely recovered at the
time of the interview, while 31 (21%) reported experiencing at
least one episode of recurrence, and 53 (36%) stated having
permanent symptoms (Table 3). Thus, the ‘‘remission’’ group
consisted of 63 patients and the ‘‘persistence’’ group included 84
individuals.
In the ‘‘persistence’’ group, all subjects reported the presence of
joint pain, the latter symptom being associated with morning
stiffness for $45 minutes in 73% of that group. Pain intensity was
rated as mild to moderate by the majority of patients (98.8%). In
this group, a reduction of daily activities as a result of their illness
was reported for .90 days in 40% of subjects.
The univariate analysis comparing the ‘‘persistence ‘‘and
‘‘remission’’ groups is presented in Table 4. Subjects aged $45
years were significantly more likely to belong to the ‘‘persistence’’
group than those aged ,45 years (OR=4.2, 95% CI 1.9–9.3).
The presence of an underlying illness was also found to be more
frequent in this group (OR=3.0, 95% CI 1.5–5.9), in particular
the presence of hypertension or osteoarthritis. On the other hand,
no such association was observed for other comorbidities. Finally,
the severity of pain at disease onset was strongly associated with
persistence (OR=3.6, 95% CI 1.6–8.1).
In the multivariate model, three variables remained indepen-
dently associated with persistence, namely age $45 years, initial
severity of joint pain, and comorbid osteoarthritis (Table 5).
Discussion
Following the massive epidemic of CHIKV infection in the
Southwest Indian Ocean region in 2005–2006, local and
international awareness of this condition increased markedly
[9,16,26]. In previous outbreaks, acute CHIKV illness was well-
documented [27], but chronic post-infectious conditions related to
Table 3. Rheumatic disease course over 15-month period
and impact among participants with confirmed CHIKV
infection (N=147), Reunion Island, 2005–2006.
Variable Subcategory
Result
(%)
Occurrence of symptoms None 63 (43)
Fluctuating 31 (21)
Persistent 53 (36)
Nature of rheumatic symptoms Pain 84 (57)
Morning stiffness
$45 minutes
61 (41)
Swelling 22 (15)
Impairment of activities of daily
living* in days
,90 50 (59.5)
90–180 24 (28.6)
.180 10 (11.9)
Joint pain intensity (NRS** score) Mild 70 (83.3)
Moderate 13 (15.5)
Severe 1 (1.2)
*In patients with persistent symptoms.
**numerical rating scale.
doi:10.1371/journal.pntd.0000389.t003
Table 4. Factors associated with persistence of rheumatic manifestations over 15-month period (univariate logistic regression
analysis) among participants with confirmed CHIKV infection (N=147), Reunion Island, 2005–2006.
Variable Subcategory Remission Group, Result (%) Persistence Group, Result (%) Odds Ratio (95 CI)*
Gender Male 23 (37) 22 (26) Reference
Female 40 (63) 62 (74) 1.6 (0.8–3.3)
Age in years ,45 26 (41) 12 (14) Reference
$45 37 (59) 72 (86) 4.2 (1.9–9.3)
Education in years 0–6 20 (32) 30 (36) Reference
7–9 29 (46) 33 (39) 0.8 (0.4–1.6)
$10 14 (22) 21 (25) 1.0 (0.4–2.4)
Presence $1 comorbidity No 40 (63) 31 (37) Reference
Yes 23 (37) 53 (63) 3.0 (1.5–5.9)
Hypertension No 49 (78) 50 (60) Reference
Yes 14 (22) 34 (40) 2.4 (1.1–4.9)
Diabetes mellitus No 54 (86) 61 (73) Reference
Yes 9 (14) 23 (27) 2.3 (0.9–5.3)
Osteoarthritis No 54 (86) 55 (65) Reference
Yes 9 (14) 29 (35) 3.2 (1.4–7.3)
Initial pain intensity (NRS**score) NRS,7 22 (35) 11 (13) Reference
NRS$7 41 (65) 73 (87) 3,6 (1,6–8,1)
*95% confidence interval.
**numerical rating scale.
doi:10.1371/journal.pntd.0000389.t004
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based study reports original data on the course of chronic
rheumatic manifestations among 147 patients infected during an
early phase of Reunion Island’s epidemic event. In this study, only
43% of patients reported full remission 15 months after acute
infection. Nearly half of the patients with persistent rheumatic pain
were impaired in carrying out daily or household activities for
more than three months. Furthermore, our findings indicate that
chronic rheumatic manifestations of CHIKV infection were
independently associated with older age at the time of infection,
severe initial pain, and the presence of comorbid osteoarthritis.
The identification of such risk factors could be relevant for early
recognition and management of patients at risk for developing
persistent rheumatic symptoms.
Few previous studies have addressed the long-term clinical
outcome of CHIKV illness. In a small case series of 28 residents of
Pretoriawithconfirmed CHIKVinfection,FourieandMorrison[22]
reported that 73% of the subjects experienced severe arthralgia in the
acute phase of the illness whereas 18% reported longstanding
rheumatic symptoms as long as 20 months after infection. In another
South African study, Brighton et al. [24] reported that 12% of 107
subjects continued to experience fluctuating or persistent rheumatic
manifestations three to five years after acute CHIKV illness.
Compared to the present study, the lower proportion rate of
persistent rheumatic manifestations may be in part related to the
interval of three to five years between illness onset and the evaluation.
Indeed, the prevalence of rheumatic symptoms associated with
Semliki Forest serocomplex viruses, namely Ross River virus, is
known to decline over time [28]. Accordingly, it appears speculative
to impute the lower prevalence principally to the population age
distribution in the Brighton study. Despite this discrepancy, Brighton
et al. [24] suggested that symptom persistence seemed more frequent
in patients aged more than 40 years, consistent with the present
findings. In addition, a recent study conducted on Reunion Island in
the setting of a hospital-based recruitment had evaluated at month
18, 88 of 202 (44%) CHIKV-infected patients who fulfill the inclusion
criteria [29]. Among these, 56 patients (63.6%) reported persistent
arthralgia, with 29 (51.8% of the 56) ascertaining a history of
arthralgia before CHIKV illness. As noted by the authors, these
results are of interest for the influence of a previous history of
rheumatic manifestations in the course of persistent arthralgia in
patientswith CHIKV infection. However,with regard to theverylow
rate of evaluated patients among those recruited, a meaningful
selection bias had probably induced an overestimation of the
proportion of persistent arthralgia. Moreover, it can be hypothesized
that the patients who had totally recovered from CHIKV illness are
less likely to comply and participate in such a followup study.
Our observation of symptom persistence in 57% of subjects is
reminiscent of findings from longitudinal studies of rheumatic
manifestations of other alphaviral infections reported from
Australia (RRV) [30,31] and Finland (Sindbis virus, SINV)
[32,33], although others have pointed out that other confounding
factors may influence the duration of rheumatic symptoms in such
diseases [34]. Hence, we recognize it can be very challenging to
differentiate between osteoarthritis and Chikungunya-related
arthralgia. This fact has been highlighted by evaluations
conducted through clinical series of CHIKV-infected patients
which clearly identified a wide range of rheumatologic manifes-
tations including tenosynovitis and lesions involving previously
injured bones or joints [35]. Nonetheless, the presence of
osteoarthritis conditions before CHIKV infection appears to be
an independent risk factor for developing late rheumatism
manifestations. Thus, further investigations should elucidate the
pathophysiologic patterns underlying this relationship.
With respect to symptom management, an important finding
was that only one-third of patients reported being satisfied with the
most prescribed class of treatment (i.e., NSAIDs). On the other
hand, treatment satisfaction with corticosteroids at any stage of the
disease was considerably higher. However, it should be empha-
sised that caution should be exercised when using corticosteroids
in such patients (infected with a virus). Nonetheless, the study
demonstrates that in practice, treatment of rheumatic symptoms of
CHIKV illness was generally inadequate. However, the role of
inadequate treatment as a potential risk factor for persistence
could not be evaluated in the present study. This issue would be
worth addressing in future studies.
This study has certain limitations that should be taken into
consideration when interpreting the results. Firstly, even if the
participation rate was high, only one-fifth of the eligible subjects
were invited to participate since telephone contact was not
available for the other subjects. Additionally, subjects under 16
years old were not eligible for the study for the reason that they are
generally less likely to answer a phone-standardized questionnaire.
Therefore, these findings may not be generalizable to all cases of
CHIKV infection that occurred on Reunion Island. Secondly,
data were collected by self-report, which precluded symptom
ascertainment by objective clinical examination. Moreover, with
subjective self-report, recall bias leading to underestimation of
either current or past symptoms cannot be excluded. Finally, this
evaluation was conducted while the second wave of the outbreak
was ongoing in 2006 [9]; in this context, the constitution of a
CHIKV antibody negative controls group for the setting of a case-
control study design appeared irrelevant. This restriction is a break
for the estimation of long-term absolute rheumatic-morbidity
attributable to CHIK-illness. These limitations, however, should
be tempered, as retrospective studies allow giving a rapid and
prompt response to health authorities by providing consistent and
relevant information and tools that will help to adapt delivered
messages to the population and the medical staff in the continuing
context of Reunion Island’s longstanding outbreak.
Table 5. Factors associated with persistence of rheumatic manifestations over 15-month period (multivariate logistic regression
analysis) among participants with confirmed CHIKV infection (N=147), Reunion Island, 2005–2006.
Variable Total Remission Group, Result (%) Persistence Group, Result (%) Odds Ratio (95%CI)* P-Value
Age $45 y 109 37 (34) 72 (66) 3.9 (1.7–9.7) 0.002
Osteoarthritis 38 9 (24) 29 (76) 2.9 (1.1–7.4) 0.029
NRS**$7 114 41 (36) 73 (64) 4.8 (1.9–12.1) 0.001
*95% confidence interval.
**numerical rating scale.
doi:10.1371/journal.pntd.0000389.t005
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CHIKV outbreak in 2005 on Reunion Island, a substantial
proportion of persistent and disabling residual rheumatic symp-
toms could be identified for at least 15 months after infection
onset, especially in individuals $45 years of age. We also identified
two other independent risk factors associated with persistence of
rheumatic symptoms that may be particularly useful in the
development and improvement of future prevention and care
strategies for this emerging viral infection. Our findings also draw
attention to the importance of assessing management issues such as
strategies for supportive treatment of CHIK illness in further
studies. Finally, these studies should be designed in order to
estimate the magnitude of chronic rheumatic illness directly
attributable to CHIKV infection and its potential effect on quality
of life over a prolonged period.
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